Letter to Investors – October
FIND OUT MORE ⟶
November 15, 2023
In this month’s Letter to Investors we discuss how the bond-driven bloodbath in share markets is throwing up some of the best valuation opportunities that we’ve seen in global small caps for years.
By Andrew Mitchell & Steven Ng Co-founders and Senior Portfolio Managers
Higher interest rates means lower share prices…Is it that simple?
FIND OUT MORE ⟶
November 15, 2023
In this month’s Investment Strategy Note we discuss the relationship between interest rates and share prices and why it’s more complicated than you think.
Letter to Investors – September
FIND OUT MORE ⟶
October 13, 2023
In this month’s Letter to Investors we analyse the impact that ripping bond yields has had specifically on small caps and how not all parts of the small cap market have been treated equally.
Resmed: Dealing with a “weighty” issue
FIND OUT MORE ⟶
October 13, 2023
In this month’s Investment Strategy Note we ‘weigh in’ with our view on the impact that GLP-1 drugs, such as Ozempic for diabetes and Wegovy for weight loss, could have on Resmed’s share price and why overall we are happy to maintain the company as a core position in the Ophir High Conviction Fund (ASX:OPH).